We are pleased to announce the launch of our Organ-Selective Lipid Nanoparticle (LNP) Delivery Service, designed to advance the development of next-generation mRNA therapeutics.

Organ-Selective mRNA Delivery with Advanced LNP Formulations

One of the key challenges in mRNA therapeutics is achieving efficient and targeted delivery to specific organs. Our advanced LNP platform addresses this challenge by enabling tunable, organ-selective delivery through optimized lipid formulation design. By fine-tuning LNP composition, we can selectively direct mRNA to hepatic (liver) and extrahepatic tissues (lung or spleen) via systemic administration, providing greater control over tissue targeting.

Key Features and Advantages

• Precise Organ Targeting
  Achieve targeted mRNA delivery to specific organs, supporting more effective and safer mRNA therapeutics.
• Extrahepatic Delivery
  Overcome one of the major barriers in mRNA-LNP drug development by enabling delivery beyond the liver.
• Flexible and Customizable Platform
  Optimize LNP formulations for various therapeutic indications and development needs.
• Robust Performance Across Manufacturing Processes
  Our LNP formulations maintain consistent quality across different LNP mixing technologies, ensuring reliable performance during scale-up and technology transfer.
• High Product Quality

Low particle size variability, high encapsulation efficiency, and stable lipid composition

Supporting Your mRNA Therapeutics Development

Our platform supports customers with scalable, high-quality LNP formulation technologies that facilitate seamless progression from early-stage research to clinical and commercial manufacturing. We are committed to accelerating innovation in mRNA therapeutics by providing reliable, flexible, and high-performance LNP delivery solutions.

The materials are available for download from “Brochures｜ARCALIS, Inc.“.